Skip to main content Accessibility help
×
Home
Hostname: page-component-846f6c7c4f-9v9hh Total loading time: 0.257 Render date: 2022-07-07T14:51:16.669Z Has data issue: true Feature Flags: { "shouldUseShareProductTool": true, "shouldUseHypothesis": true, "isUnsiloEnabled": true, "useRatesEcommerce": false, "useNewApi": true } hasContentIssue true

Sertindole in the treatment of tardive dyskinesia in a patient with genetically abnormal dopamine D3 receptors

Published online by Cambridge University Press:  24 June 2014

Emmanouil N. Rizos*
Affiliation:
National and Kapodistrian University of Athens, Medical School, Second Department of Psychiatry, “ATTIKON” General Hospital, Athens, Greece National and Kapodistrian University of Athens, Medical School, Second Department of Psychiatry, Clinical and Molecular Psychogenetic Unit “ATTIKON” General Hospital, Athens, Greece
Athanasios Douzenis
Affiliation:
National and Kapodistrian University of Athens, Medical School, Second Department of Psychiatry, “ATTIKON” General Hospital, Athens, Greece
Ioannis Michopoulos
Affiliation:
National and Kapodistrian University of Athens, Medical School, Second Department of Psychiatry, “ATTIKON” General Hospital, Athens, Greece
Nikolaos Siafakas
Affiliation:
National and Kapodistrian University of Athens, Medical School, Laboratory of Clinical Microbiology, “ATTIKON” General Hospital, Athens, Greece
Eleni Katsantoni
Affiliation:
Biomedical Research Foundation, Academy of Athens, Hematology-Oncology Division, Athens, Greece
Rossetos Gournellis
Affiliation:
National and Kapodistrian University of Athens, Medical School, Second Department of Psychiatry, “ATTIKON” General Hospital, Athens, Greece
Lefteris Lykouras
Affiliation:
National and Kapodistrian University of Athens, Medical School, Second Department of Psychiatry, “ATTIKON” General Hospital, Athens, Greece
*
Emmanouil N. Rizos Lecturer in Psychiatry, National and Kapodistrian University of Athens, Medical School, Second Department of Psychiatry, “ATTIKON” General Hospital, 1 Rimini str., 12462 Athens, Greece. Tel: +302105832426; Fax: +302105326453; E-mail: erizos@med.uoa.gr

Abstract

Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Comment & Critique
Copyright
Copyright © 2010 John Wiley & Sons A/S

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Lerer, B, Segman, RH, Fangerau, Het al. Pharmacogenetics of tardive dyskinesia: combined analysis of 780 patients supports association with dopamine D3 receptor gene Ser9Glypolymorphism. Neuropsy-chopharmacology 2002;27:105119. Google Scholar
American Psychiatric Association. APA Practice Guidelines for the treatment of psychiatric disorders-compendium. Washington DC: APA, 2004: 344. Google Scholar
Taylor, D, Paton, C, Kerwin, R.The South London and NHS Foundation Trust Oxleas NHS Foundation Trust: Prescribing Guidelines, 9th edn. Bodmin Cornwall UK: MPG Books, 2007: 99. Google Scholar
Llorca, PM, Cherau, I, Bayle, FJ, Lancon, C.Tardive dyskinesia and antipsychotics: a review. Eur Psychiatry 2002;17:129138. Google Scholar
Steen, VM, Lovelie, R, MacEvan, T, McCreadie, RG.Dopamine D3 receptor gene variant and susceptibility to tardive dyskinesia in schizophrenic patients. Mol Psychiatry 1997;2:139145. Google Scholar
Spina, E, Zoccali, R.Sertindole: pharmacological and clinical profile and role in the treatment of schizophrenia. Exp Opin Drug Metab Toxicol 2008;4:629638. Google Scholar
Hale, A, Azorin, JM, Kasper, Set al. Sertindole improves both the positive and negative symptoms of schizophrenia: results of a phase III trial. Int J Psychiatry Clin Pract 2000;4:5562. Google Scholar
Perquin, L.Treatment with the new antipsychotic sertindole for late-occurring undesirable movement effects. Int Clin Psychopharmacol 2005;20:335338. Google Scholar
2
Cited by

Save article to Kindle

To save this article to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Sertindole in the treatment of tardive dyskinesia in a patient with genetically abnormal dopamine D3 receptors
Available formats
×

Save article to Dropbox

To save this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you used this feature, you will be asked to authorise Cambridge Core to connect with your Dropbox account. Find out more about saving content to Dropbox.

Sertindole in the treatment of tardive dyskinesia in a patient with genetically abnormal dopamine D3 receptors
Available formats
×

Save article to Google Drive

To save this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you used this feature, you will be asked to authorise Cambridge Core to connect with your Google Drive account. Find out more about saving content to Google Drive.

Sertindole in the treatment of tardive dyskinesia in a patient with genetically abnormal dopamine D3 receptors
Available formats
×
×

Reply to: Submit a response

Please enter your response.

Your details

Please enter a valid email address.

Conflicting interests

Do you have any conflicting interests? *